1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Wuhan Easy Diagnosis Biomedicine Co., Ltd. Class A

Wuhan Easy Diagnosis Biomedicine Co., Ltd. Class A

SSZSE:002932
14.40
CNY
+0.01
(+0.07%)
3.34BMarket Cap
Oct 31Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.02
0.41
0.63
0.91
1.06
1
0.87
4.6
13.37
46.19
3.3
1.55
1.13
- -
Basic EPS, GAAP
0.85
0.15
0.23
0.39
0.42
0.35
0.2
2.25
6.68
18.46
0.33
0.33
-0.07
- -
Free Cash Flow per Basic Share
0.41
0.09
0.29
0.12
0.01
0.04
-0.05
1.59
4.84
16.23
1.24
-1.19
-0.68
- -
Dividend per Share
0.01
0.02
0.03
- -
- -
0.15
0.1
0.04
1.34
2.42
2.57
0.15
1.12
0.1
Book Value per Share
0.09
0.32
0.74
1.13
1.55
2.84
2.95
5.14
11.98
27.93
25.92
25.06
23.78
23.02
Tangible Book Value per Share
0.07
0.3
0.73
1.11
1.43
2.76
2.86
5.06
11.91
27.86
25.84
24.98
23.66
22.8
Basic Weighted Avg Shares
9
142
152
155
155
177
208
209
212
228
227
226
235
217
Sales/Revenue/Turnover
26
58
95
141
165
176
181
959
2,830
10,530
750
350
265
- -
Operating Margin (%)
31.66
38.32
42.42
47.04
44.9
36.84
19.05
58.88
60.52
57.2
13.36
-4.19
-39.97
- -
Depreciation Expense
- -
1
2
4
10
13
17
17
24
59
83
63
54
- -
Net Income, GAAP
7
22
36
60
65
61
42
469
1,413
4,208
75
75
-16
- -
Effective Tax Rate (%)
15.23
13.45
14.21
13.63
13.09
11.81
8.69
14.56
14.63
13.71
50.52
18.05
- -
- -
Profit Margin (%)
28.22
37.26
37.34
42.34
39.66
34.82
22.92
48.89
49.94
39.97
10
21.29
-6.21
- -
Working Capital
3
36
100
124
155
484
452
907
2,454
5,317
1,731
1,902
4,442
4,237
LT Debt
- -
- -
- -
- -
- -
- -
- -
5
11
21
18
6
3
15
Total Equity
14
50
115
175
243
593
616
1,115
2,850
6,772
6,292
6,019
5,656
5,473
Return on Invested Capital (%)
84.44
56.07
41.28
39.24
31.21
14.31
6.26
50.64
67.37
89.75
1.14
0.59
- -
- -
Return on Capital (%)
91.98
65.42
42.7
41.1
31.31
14.44
6.68
49.27
66.46
81.85
1.29
2
- -
- -
Return on Common Equity (%)
97.51
68.18
43.15
41.1
31.51
14.82
6.93
54.8
72.65
90.61
1.2
1.26
-0.29
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5
14
16
LT Borrowings
- -
- -
6
LT Finance Leases
3
10
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
233
233
233
Market Capitalization
4,460
3,732
3,337

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,683
4,699
4,477
Cash, Cash Equivalents & STI
905
2,852
3,672
Accounts Receivable, Net
466
449
377
Inventories
65
96
112
Total Current Liabilities
241
256
240
Payables & Accruals
- -
- -
- -
ST Debt
5
14
16
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
59.52%
55.16%
-6.03%
Free Cash Flow
-333.67%
28.42%
-40.35%
Net Income, GAAP
124.63%
35.66%
-122.09%
Sales/Revenue/Turnover
80.07%
59.34%
-24.28%
Total Cash Common Dividend
- -
786.54%
670.09%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
61
93
71
124
350
2025
70
69
- -
38
265
2026
71
71
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.15
0.07
-0.03
0.33
2025
-0.02
0.07
- -
-0.14
-0.07
2026
- -
-0.1
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.12
- -
0.09
0.15
2025
- -
1.2
- -
- -
1.12
2026
- -
0.11
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Li Li Chen
Full Time Employees
599
Sector
Health technology
Industry
Medical specialties
Address
East Lake New Technology Development Zone Wuhan HB China 430075
IPO Date
Jul 10, 2018
Website
mdeasydiagnosis.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Wuhan Easy Diagnosis Biomedicine Co., Ltd. (002932.SZ) develops, manufactures, and sells in vitro diagnostic reagents and instruments primarily focused on biomedical testing for infectious diseases, autoimmune conditions, and clinical chemistry. The company offers core products including chemiluminescence immunoassay analyzers and reagents under its proprietary brands such as EasyDiagnosis series; time-resolved fluorescence immunoassay kits for items like thyroid function, tumor markers, and fertility hormones; colloidal gold rapid test kits for COVID-19 antigens, HIV, and hepatitis; and supporting instruments like automatic biochemical analyzers and microplate readers. These products serve hospitals, clinics, and diagnostic laboratories mainly in China, with expanding operations in Asia and select international markets. Founded in 2003 and headquartered in Wuhan, Hubei Province, China, the company operates in the medical diagnostics segment of the healthcare industry, targeting primary healthcare providers and large-scale testing facilities. It maintains a network of subsidiaries for research, production, and distribution across multiple provinces in China, emphasizing rapid diagnostic solutions for point-of-care testing. In recent developments, Wuhan Easy Diagnosis Biomedicine expanded its product portfolio with new chemiluminescence immunoassay reagents for cardiac markers and inflammation detection launched in 2024; formed strategic partnerships with regional hospitals for customized diagnostic solutions; and completed a funding round in late 2024 to support R&D in molecular diagnostics amid post-pandemic demand. The company also reorganized its operations to enhance supply chain resilience following global disruptions, with no major acquisitions or name changes reported in the last two years.